Puyang Huicheng Electronic Material (300481)

Search documents
濮阳惠成:关于首次回购公司股份的公告
2024-04-11 09:34
濮阳惠成电子材料股份有限公司 证券代码:300481 证券简称:濮阳惠成 公告编号:2024-028 濮阳惠成电子材料股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 濮阳惠成电子材料股份有限公司(以下简称"公司")第五届董事会第七次 会议审议通过了《关于公司股份回购方案的议案》。公司拟使用自有资金通过深 圳证券交易所交易系统以集中竞价交易方式回购公司部分人民币普通股 A 股股 份(以下简称"本次回购"),用于后续实施股权激励或员工持股计划等。本次 回购的资金总额不低于人民币 5,000 万元(含),不超过人民币 10,000 万元(含), 回购股份的价格为不超过 26.3 元/股,该回购价格上限未超过公司董事会审议通 过回购股份方案决议前 30 个交易日公司股票交易均价的 150%,回购股份的实施 期限为自公司董事会审议通过回购股份方案之日起不超过 12 个月。具体内容详 见公司于 2023 年 12 月 19 日在巨潮资讯网披露的《关于公司回购股份方案的公 告》(公告编号:2023-099)。 一、首次股份回购的进展情况 2024 年 4 月 ...
公司信息更新报告:公司业绩压力释放,或将重归稳健增长轨道
KAIYUAN SECURITIES· 2024-04-02 16:00
濮阳惠成(300481.SZ) 2024 年 04 月 03 日 股价走势图 《Q1 业绩同比略有下滑,看好公司长 期发展 — 公 司 信 息 更 新 报 告 》 -2023.4.26 2023 年,公司顺酐酸酐衍生物销量 8.22 万吨,同比增长 21.69%,产能利用率高 达 113.47%,其中用于风电用途占比达 10%以上;实现营收 9.95 亿元,同比下 降 18.72%。据中国电力网数据,2024 年国家电网建设投资总规模预计超 5000 亿元;据国际能源网数据,据 14 个省市的 2024 年风电项目规划,规模总计达 96.19GW。电网投资保持高强度叠加风电建设加速,顺酐酸酐需求有望保持较高 增长。公司清洋项目以及古雷项目也将保障公司顺酐酸酐业务的长期成长。 | --- | --- | --- | --- | --- | --- | |--------------------------------|-------|-------|-------|-------|-------| | 财务摘要和估值指标 指标 | 2022A | 2023A | 2024E | 2025E | 2026E | ...
濮阳惠成:关于通过高新技术企业认定的公告
2024-04-02 10:01
证券代码:300481 证券简称:濮阳惠成 公告编号:2024-026 濮阳惠成电子材料股份有限公司 濮阳惠成电子材料股份有限公司 关于公司全资子公司通过高新技术企业认定的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 一、基本情况 濮阳惠成电子材料股份有限公司全资子公司山东清洋新材料有限公司(以下 简称"山东清洋")于近日收到山东省科学技术厅、山东省财政厅、国家税务总 局山东省税务局联合颁发的《高新技术企业证书》,证书编号为GR202337000557, 发证日期:2023年11月29日,有效期三年。 根据相关规定,山东清洋自通过高新技术企业重新认定起连续三年可继续享 受国家关于高新技术企业的税收优惠政策,即按15%的税率缴纳企业所得税。本 次山东清洋获得《高新技术企业证书》为通过高新技术企业复审之后再次获得, 该事项不会对公司经营业绩产生重大影响 山东清洋通过国家高新技术企业认定,是对山东清洋在技术研发和自主创新 方面的肯定和鼓励,是其持续发展能力的综合表现,有助于公司进一步夯实未来 发展战略,持续提升公司整体的创新能力和综合竞争力。 二、备查文件目 ...
2023年年报点评:顺酐酸酐衍生物量升价减23年业绩下降,关注公司募投项目落地进展
EBSCN· 2024-04-01 16:00
顺酐酸酐衍生物量升价减 23 年业绩下降,关注公司募投项目落地进展 | --- | --- | --- | --- | --- | --- | |-----------------------------------|--------|---------|--------|--------|--------| | 指标 2022 2023 2024E 2025E 2026E | | | | | | | 营业收入(百万元) | 1,597 | 1,379 | 1,626 | 1,863 | 2,107 | | 营业收入增长率 | 14.62% | -13.63% | 17.90% | 14.59% | 13.09% | | 净利润(百万元) | 422 | 235 | 297 | 353 | 401 | | 净利润增长率 | 67.14% | -44.32% | 26.27% | 18.89% | 13.61% | | EPS (元) | 1.42 | 0.79 | 1.00 | 1.19 | 1.35 | | ROE (归属母公司)(摊薄) | 18.20% | 9.61% | 11.31% | 12.22% ...
顺酐酸酐衍生物量升价跌,功能中间体毛利率显著提升,Q4单季度业绩短期承压
申万宏源· 2024-03-31 16:00
上 市 公 司 证 券 研 究 报 告 电子 公 司 研 究 / 公 司 点 评 | --- | --- | |-----------------------------|-------------------------------| | 市场数据: | 2024 年 03 月 29 日 | | 收盘价(元) | 13.02 | | 一年内最高 / 最低(元) | 27.72/10.32 | | 市净率 | 1.6 | | 息率(分红/ 股价) | | | 流通 A 股市值(百万元) | 3827 | | 上证指数/深证成指 | 3041.17/9400.85 | | --- | --- | |----------------------------------------------|-------------------------------| | | | | 基础数据 : | 2023 年 12 月 31 日 | | | | | 每股净资产(元) | 8.25 13.32 | | 资产负债率 % 总股本/ 流通 A 股(百万) | 296/294 | | 流通 B 股 /H 股(百万) | -/- ...
濮阳惠成(300481) - 2023 Q4 - 年度财报
2024-03-29 16:00
Financial Performance - The company's operating revenue for 2023 was approximately ¥1.38 billion, a decrease of 13.63% compared to ¥1.60 billion in 2022 [22]. - The net profit attributable to shareholders for 2023 was approximately ¥235.12 million, down 44.32% from ¥422.30 million in 2022 [22]. - The basic earnings per share for 2023 was ¥0.80, a decline of 44.06% from ¥1.43 in 2022 [22]. - The total assets at the end of 2023 were approximately ¥2.82 billion, reflecting a slight increase of 0.61% from ¥2.80 billion at the end of 2022 [22]. - The company's operating revenue for 2023 was CNY 1,379,201,434.04, a decrease of 13.63% compared to the previous year [54]. - The net profit attributable to shareholders was CNY 23,512,220.00, down 44.32% year-on-year [54]. - Revenue from maleic anhydride derivatives was CNY 994,554,040.86, representing 72.11% of total revenue, and decreased by 18.72% year-on-year [56]. - The sales volume of maleic anhydride derivatives reached 82,200 tons, an increase of 21.69% year-on-year, with over 10% of this volume used in the wind power sector [54]. Dividend Distribution - The company plans to distribute a cash dividend of 4 RMB per 10 shares to all shareholders, based on a total of 296,358,747 shares [3]. - The company has not proposed any bonus shares or capital reserve transfers in the profit distribution plan [3]. - The company reported a cash dividend of 4.00 RMB per 10 shares, totaling 118,543,498.80 RMB for the year, which represents 100% of the total profit distribution [135]. - The company has a total of 704,391,768.72 RMB in distributable profits, confirming its profitability during the reporting period [135]. Research and Development - The company is actively developing new products and has established a professional R&D team to quickly respond to market demands and optimize production processes [40]. - The company plans to enhance its R&D capabilities by focusing on new product development in areas such as optoelectronic materials and pharmaceutical intermediates [53]. - The company reported a 6.83% increase in R&D expenses, totaling CNY 79,192,246.67 for 2023 [65]. - The number of R&D personnel increased by 17.96% to 197, with R&D personnel now accounting for 26.69% of the total workforce [66]. - R&D investment amounted to ¥79,192,246.67, representing 5.74% of operating revenue, an increase from 4.64% in the previous year [67]. - The company plans to strengthen its R&D team and focus on research in functional material intermediates to enhance sustainable development [95]. Market Position and Competition - The company is positioned as a leading player in the domestic market for anhydride derivatives, benefiting from industry chain advantages and stable customer resources [33]. - The competitive landscape in the chemical industry has intensified, impacting the company's ability to maintain product margins [33]. - The company holds a leading position in the domestic market for anhydride derivatives, but faces increasing competition from new entrants [98]. - The company is focused on enhancing its competitive advantages through technology and product quality improvements to maintain market position [99]. Risk Management - The company has outlined potential risk factors in its future development outlook section, which investors should pay attention to [3]. - The company faces risks from downstream industry slowdowns, particularly in the demand for its anhydride derivatives, which could impact growth [96]. - The company is exposed to significant risks from raw material price fluctuations, which can directly affect production costs and profit margins [97]. - The company has implemented measures to mitigate accounts receivable risks, including strict internal management and credit control based on customer classification [97]. Corporate Governance - The company has established a performance evaluation and incentive system for its directors, supervisors, and senior management, ensuring transparency and compliance with legal regulations [104]. - The company maintains independence from its controlling shareholders in terms of business operations, personnel, assets, and financial management, demonstrating complete operational autonomy [107]. - The company has a well-structured corporate governance framework, including a board of directors, supervisory board, and management team, adhering to legal requirements [107]. - The company has a dedicated board secretary responsible for coordinating investor relations and ensuring timely information disclosure [104]. Environmental Compliance - The company is compliant with various environmental protection laws and regulations, ensuring legal and regulatory adherence in its operations [144]. - The company emphasizes strict adherence to national environmental protection laws and regulations, with a focus on managing waste gas and wastewater emissions [150]. - The company reported that all monitored pollutants met standards during the reporting period, with no exceedances recorded [151]. - Environmental protection tax was paid in accordance with legal requirements, reflecting the company's commitment to environmental compliance [152]. Employee Management - The total number of employees at the end of the reporting period was 738, with 390 in production, 22 in sales, 219 in technology, 14 in finance, and 93 in administration [130]. - The employee training program is designed to enhance business capabilities and skills, aligning with the company's long-term strategic goals [132]. - The company has no outsourced labor, indicating a fully in-house operational strategy [134]. - The company emphasizes the importance of talent development and aims to build a professional management team to support sustainable growth [93]. Strategic Initiatives - The company plans to expand its market presence and invest in new product development to enhance competitiveness [114]. - The company aims to optimize product structure and enhance technical innovation capabilities in the anhydride derivatives market, targeting to become the leading brand in this sector in China [89]. - The company is focusing on enhancing its research and development capabilities to support new product launches [115]. - The company plans to deepen its understanding of customer needs to guide consumption trends and optimize its customer structure [93].
濮阳惠成:关于修订公司独立董事工作制度的公告
2024-03-29 10:35
濮阳惠成电子材料股份有限公司 证券代码:300481 证券简称:濮阳惠成 公告编号:2024-023 濮阳惠成电子材料股份有限公司 | 原制度 | 修订后 | | --- | --- | | (六)法律、行政法规、中国证监会规定和公司 | (六)法律、行政法规、中国证监会规定和公司 | | 章程规定的其他职权。 | 章程规定的其他职权。 | | 独立董事行使前款第一项至第三项所列职权 | 独立董事行使前款第一项至第三项所列职权 | | 的,应当经全体独立董事过半数同意。 | 的,应当经全体独立董事过半数同意。 | | 独立董事行使第一款所列职权的,公司应当及 | 独立董事行使第一款所列职权的,公司应当及 | | 时披露。上述职权不能正常行使的,公司应当披露 | 时披露。上述职权不能正常行使的,公司应当披露 | | 具体情况和理由。 | 具体情况和理由。 | | 独立董事聘请中介机构的费用及其他行使职 | 独立董事聘请中介机构的费用及其他行使职 | | 权时所需的费用由公司承担。 | 权时所需的费用由公司承担。 | | | 独立董事认为现金分红具体方案可能损害上 | | | 市公司或者中小股东权益的,有权发表独 ...
濮阳惠成:关于公司续聘审计机构的公告
2024-03-29 10:35
濮阳惠成电子材料股份有限公司 (一)机构信息 1.基本信息 证券代码:300481 证券简称:濮阳惠成 公告编号:2024-022 濮阳惠成电子材料股份有限公司 关于公司续聘审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 一、拟聘任会计师事务所事项的情况说明 立信会计师事务所(特殊普通合伙)具有证券从业资格,具备为上市公司提 供审计服务的经验与能力,在为公司提供审计服务的工作中,能够遵循独立、客 观、公正的职业准则,恪尽职守,为公司提供了高质量的审计服务,其出具的报 告能够客观、真实地反映公司的实际情况、财务状况和经营成果,切实履行了审 计机构职责,从专业角度维护了公司及股东的合法权益。基于上述原因,公司拟 续聘立信会计师事务所(特殊普通合伙)为公司2024年度审计机构。 二、拟聘任会计师事务所的基本信息 截至2023年末,立信已提取职业风险基金1.61亿元,购买的职业保险累计赔 偿限额为12.50亿元,相关职业保险能够覆盖因审计失败导致的民事赔偿责任。 | 起诉 (仲 | 被诉(被仲裁)人 | 诉讼(仲裁) | 诉讼(仲 | 诉讼(仲裁)结果 ...
濮阳惠成:独立董事述职报告(任保增)
2024-03-29 10:35
濮阳惠成电子材料股份有限公司 2023 年度独立董事述职报告 (任保增) 一、基本情况 1.独立董事工作履历、专业背景及兼职情况 2.独立性说明 在担任公司独立董事期间,本人未在公司担任除独立董事以外的任何职务, 也未在公司主要股东公司担任任何职务,与公司以及主要股东之间不存在妨碍本 人进行独立客观判断的关系,不存在影响独立董事独立性的情况,符合《上市公 司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等法律、法规、规范性文件及《公司章程》《独立董事工 作制度》中关于独立董事独立性的相关要求。 各位股东: 二、2023 年度履职情况 本人作为濮阳惠成电子材料股份有限公司(以下简称"公司")的独立董事, 严格按照《公司法》《证券法》《上市公司治理准则》和《上市公司独立董事履 职指引》等法律法规和《公司章程》《独立董事工作制度》等的规定,认真履行 职责,积极参加公司召开的董事会和相关专业委员会会议,认真审议各项议案, 对公司重大事项发表独立意见,充分发挥独立董事的作用,监督公司规范化运作, 维护了公司整体利益及全体股东的合法权益。现将 2023 年度本人履行独立董事 ...